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Abstract
“Suppressors of cytokine signalling” (SOCS) protein induction via the “Janus kinase- 
signal transducer and activator of transcription” (JAK-STAT) pathway has been 
shown to be a critical negative feedback mechanism that prevents inappropriately 
sustained signalling from activated cytokine receptors. It also provides a mechanism 
by which other signalling modules could potentially regulate the JAK-STAT pathway. 
In this study, I have demonstrated that elevation of the prototypical second messenger 
cyclic AMP (cAMP) is capable of promoting the time- and concentration-dependent 
accumulation of the SOCS-3 isoform in U937 human promyeloid cells and HL60 
human promyoblast cells. Experiments with MG 132 demonstrated that cAMP 
specifically promoted SOCS-3 synthesis rather than blocking its degradation by the 
proteasome. The accumulation of SOCS-3 in U937 cells correlated with a reduced 
ability of the granulocyte-colony stimulating factor (G-CSF) receptor, which is a bona 
fide target for SOCS-3 in vivo, to promote the Tyr phosphorylation of STAT3 and the 
dual Thr/Tyr phosphorylation of ERK, suggesting that the cAMP-mediated 
accumulation of SOCS-3 is sufficient to suppress JAK-STAT pathway activation by 
this receptor. Further characterisation of the response demonstrated that SOCS-3 
induction could not be blocked by H89, an inhibitor of cAMP-dependent protein 
kinase (PKA), suggesting that a PKA-independent mechanism was responsible. 
Consistent with this hypothesis, selective activation of PKA with the selective cAMP 
analogue 6Be-cAMP failed to promote SOCS-3 accumulation. Surprisingly, selective 
activation of “Exchange protein activated by cAMP” (Epac), a recently identified 
PKA-independent intracellular sensor of cAMP, using the cAMP analogue 8pCPT- 
20Me-cAMP also failed to promote SOCS-3 accumulation. Moreover, the inability 
of both 6Be-cAMP and 8pCPT-20Me-cAMP to promote SOCS-3 accumulation was
IV
not due to a lack of biological activity, since both were able to stimulate the 
phosphorylation of ERK in U937 cells at the concentrations used to assess SOCS-3 
induction. Finally, preliminary experiments employing inhibitors of various 
signalling pathways revealed that cAMP-mediated SOCS-3 accumulation occurred 
via a JAK-, p38- and ERK-independent mechanism. Thus, it is proposed that cAMP 
elevation may promote the accumulation of SOCS-3 in U937 cells via a novel 
pathway leading to increased SOCS-3 synthesis that is independent of the known 
cAMP sensors PKA and Epac, and which may thus involve a currently unknown 
intracellular sensor of cAMP.
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CHAPTER 1
Introduction
1.1 Inflammation
Inflammation is a beneficial host reaction in response to foreign challenge or tissue 
injury and leads ultimately to the restoration of tissue stmcture and function 
{Lawrence et al, 2002). Several mechanisms have evolved to render this process an 
effective, intricately controlled self-limiting event. However, imbalance in this system 
often occurs resulting in pathological damage.
In the preliminary stages of the inflammatory response, there is sequential release of 
mediators, particularly inflammatoiy cytokines, and subsequent recmitment of 
circulating leukocytes {Park et al, 2004). Under normal physiological conditions, the 
inflammatory response is resolved by accumulation of intracellular negative 
regulatory factors. However with certain disease states, attenuation of inflammatory 
events does not occur {Lawrence et al, 2002). This is presumably due to failure of 
negative regulatory pathways, resulting in persistent accumulation and activation of 
leukocytes, a symptom of chronic inflammation.
Current treatment strategies for chronic inflammation focus on inhibition of pro- 
inflammatory mediators, thereby suppressing initiation and maintenance of the 
inflammatory response. Naturally, elucidation of the signalling events involved in 
endogenous negative regulatory pathways of the inflammatory response would lead to 
a greater pool of targets for pharmacological intervention.
Transduction pathways of well-characterised pro-inflammatory cytokines such as 
interleukin -1 (IL-1), tumour necrosis factor- a  (TNFa), IL-12, IL-18, granulocyte-
macrophage-colony stimulating factor (GM-CSF) and granulocyte-colony stimulating 
factor (G-CSF) have been extensively studied. This has shown that many cytokines 
are able to exert pluripotent biological effects through activation of Janus kinases 
(JAKs) and signal transducer and activator of transcription (STAT) proteins 
(Kisseleva et al, 2002).
Until recently, relatively little work has been done to establish a detailed evaluation of 
the negative-feedback pathways of inflammation. Suppressors of cytokine signalling 
(SOCS) proteins function as inhibitors of cytokine receptor signalling by inhibiting 
the JAK/STAT signal transduction pathway {Suzuki et al, 2001). It has now emerged 
that SOCS are instrumental in the negative regulation of cytokine responses and 
furthermore may provide a clinical target for therapeutic intervention in the disease 
states associated with excessive inflammation {Alexander., 2002).
This study will consider the possible pathways involved in regulation of SOCS3 
expression in two pro-monocytic cell lines under vaiying conditions.
1.2 Haematopoeisis
Every 60 seconds a human being generates about 120 million granulocytes and 150 
million erythrocytes, as well as numerous mononuclear cells and platelets {Rang, et, 
al, 2000). The cells responsible for this remarkable productivity are derived from a 
relatively small number of self-renewing pluripotent stem cells laid down during 
embryogenesis {Kuijpers et al, 2001). The process is regulated by a complex array of 
haematopoietic growth factors, which act to direct the division, maturation and 
functional activity of the end-stage cells {Kuijpers et al, 2001).
1.2.1 Cytokine regulation of haematopoeisis
Proliferation, differentiation and functional activities of haematopoietic cells are 
regulated by a diverse group of protein factors, refeiTed to collectively as the ‘colony- 
stimulating factors’. They include the macrophage colony stimulating factor (M- 
CSF), granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage- 
colony stimulating factor (GM-CSF) and the multi-colony stimulating factor also 
know as interleukin-3 (Multi-CSF or IL-3) {Smithgall, 1998).
This study focuses on the effects of G-CSF and GM-CSF, which act synergistically to 
promote maximal outgrowth of various lingeages of cells. Indeed, G-CSF is the 
primary extracellular regulator of granulopoiesis, affecting the proliferation, suiwival 
and differentiation of all cells within the granulocytic lineage, from haematopoietic 
stem cells through to mature neutrophils (Lieschke et.al.,1994)
1.3 Common cytokine signalling pathways
1.3.1 JAK/STAT pathway
The JAK/STAT pathway is used to transduce a multitude of signals for development 
and homeostasis. Indeed, it forms the principal signalling mechanism for a wide 
variety a cytokines and growth factors, such as interleukin-6 (IL-6), via the gpl30 
subunit of the IL-6 receptor complex and growth hormone (GFI) (Ilangumaran, et. al, 
2004).
In mammals, the JAK family comprises four members: JAKl, JAK2, JAK3 and Tyk2. 
JAKs share seven regions of high homology, JH1-JH7 and are distinctive because 
they contain tandem kinase-homologous domains at the C-terminus {Kisseleva et al,
2002) Figure LI. JHl encodes the functional kinase domain and is known to possess 
classical features of a tyrosine kinase receptor {Hubbard and Till, 2000). These 
include conserved tyrosines that form a critical component o f the activation loop; 
Y1038/Y1039 in JAKl, Y1007/Y1008 in JAK2, Y980/Y981 in JAK3, Y1054/Y1055 
in Tyk2 {Leonard et a i, 1998). JH2 represents a pseudokinase domain or kinase-like 
(KL) domain which shares all the structural features of a tyrosine kinase, except 
catalytic activity. The KL domain appears to regulate JHl catalytic activity {Yeh et 
al,. 2000) and is essential for proper JAK function. For example, deletion studies have 
found that Jak2 becomes hyperactivated in the absence of the KL domain {Leonard et 
al,.1998). The amino terminus (JH3-JH7) spans 550 amino acids and has been 
functionally implicated in receptor association, and binding specificity. However, the 
role o f the JH7 region in this interaction remains undefined {Kisseleva et al., 2002).
STAT Afnno term II ai
JAK J tn JHS
Recept or Bntf ng R e^on Pseudoknsse
Domain
10 nose 
Domati
p iqo 2qo 390 4qo 590 sço zqo ago gqo iopo ngo 1200
Figure 1.1 Diagram o f JAK and STAT structure. (Kisseleva, et.ai,2002)
Seven STAT proteins have been identified in mammals; Statl, Stat2, Stat3, Stat4, 
Stat5a, Stat5b and Stat6 {Kisseleva et a i, 2002). The members o f this family range in 
size from 750 to 850 amino acids and share structurally and functionally conserved 
domains including an amino-terminal domain (NH2), a coiled- coiled domain (CCD),
the DNA binding domain (DBD), the linker domain and the SH2/tyrosine activation 
domain {Kisseleva et al, 2002). The SH2 domains are the most highly conserved 
STAT domain as it is linked to their role in receptor signalling where they are 
required to bind specific phosphotyrosine motifs {Kawata et al 1997). This high level 
specificity is important for three of the main events involved in STAT signalling. 
These include 1) recmitment of STAT to the cytokine receptor, 2) association of 
STAT with the activating JAK {Barahmand-Pour et al, 1998), and 3) the process of 
STAT dimérisation {Gupta et al 1996). The C-terminal region contains a 
transcriptional activation domain (TAD) which varies between members of the STAT 
family thereby contributing to STAT specificity {Kisseleva et al, 2002). Significant 
specificity is achieved in part, due to the fact that receptors capable of signal 
transduction via STATs are divided into five stmcturally and functionally related 
families. Tissue specific patterns of expression of ligands and receptors, as well as 
activation of additional signalling pathways by these receptors also influence the 
specificity of STAT activity.
The JAK/STAT pathway is initiated when ligand binding induces the multimerization 
of specific receptor subunits. In order for signal propagation to occur, the cytoplasmic 
domains of two receptor subrmits must be associated with JAK tyrosine kinases 
{Rawlings et al 2004). Following ligand binding, multimerization results in two JAKs 
being brought into close proximity thereby allowing trans-phosphorylation. The 
activated JAKs subsequently phosphorylate additional targets, including both 
receptors and STATs {Rawlings et al 2004).
STATs are thought to reside latent in the cytoplasm until activated by JAKs via 
phosphorylation of a consei*ved tyrosine residue near their C-terminus. It is known 
that complete activation of STATl requires phosphorylation at both Y701 and a 
conserved PMS(727)P sequence, while STAT5 is tyrosine phosphorylated at Y694 
{Rane et al, 2002) and STAT3 requires phosphorylation of Y705. The 
phosphotyrosine allows STAT dimérisation to occur through interaction with a 
conserved SH2 domain. The phosphorylated STAT dimers then enter the nucleus 
where they bind specific regulatory sequences to activate or repress transcription of 
target genes. Essentially the JAK/STAT pathway is a mechanism by which an 
extracellular signal can be translated into a transcriptional response {Rawlings et al, 
2004).
Predictably, mutations that constitutively activate or fail to regulate JAK/STAT 
signalling properly are the cause of inflammatoiy disease, erythrocytosis, gigantism 
and a range of leukemias {Touw, et al, 2000).
1.3.2 Ras/Raf/Mitogen activated Protein Kinase (ERK)Pathway
Ras is an essential downstream component of most tyrosine kinase signal transduction 
pathways. Receptor activation leads to rapid conversion of inactive, GDP-bound Ras 
to the active GTP-bound state. This process is positively controlled by protein factors, 
known as guanine nucleotide exchange factors (GEFs) that promote GDP-GTP 
exchange and negatively regulated by GTPase-activating proteins (GAPs) which 
accelerate the intrinsic GTPase activity of Ras thereby promoting termination of the 
Ras signal {Rang et al,2000). These regulatory proteins provide a biochemical link 
between Ras activation and tyrosine kinases via their SH2 domains. For example
autophosphorylated growth factor receptors interact directly with a GEF complex 
comprising growth factor receptor binder/son of sevenless (Grb2/S0S), consisting of 
a Ras GEF (SOS) coupled to an SH2 containing adaptor protein (Grb2) {Cobb et al,
1996). The SH2 domain of Grb2 serves to bring the complex into direct contact with 
specific autophosphorylated tyrosines on the activated growth factor receptor. The net 
effect of the process is to relocate the exchange activity form the cytoplasm to the 
plasma membrane where it will be brought into proximity to Ras to promote the 
guanine nucleotide exchange interaction (Schlessinger,. 1993). Figure 1.2
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Figure 1.2 Cytokine receptor activation o f small G-protein/MAPK pathways
The GTP-bound Ras undergoes a conformational change enabling activation of 
downstream target proteins, the best characterised protein being Rafl {Morrison et al,
1997). In the case of cytokine receptors, the tyrosine phosphorylation of Raf may be 
mediated by Jak2 {Xia et al, 1996) or possibly a member of the Src kinase family
{Fabian et al, 1993). Once bound to Ras-GTP, Rafl is relocated from cytoplasm to 
the plasma membrane. Rafl then goes onto activate the dual specificity MAP kinase 
kinases, often referred to as MEKs, which intum activate the MAP kinases, ERK-1 by 
phosphorylating Thr 183 and Tyr 185 and ERK-2 via phosphoiylation of Thr 202 and 
Tyr 204 {www.embbiosciences.com). Activated ERKs are able to translocate into the 
nucleus where they are able to phosphorylate a variety of transcription factors, these 
include SMK-1, c-myc (Thr58/Ser62), ELK-1 (Ser838) and STATS 
{www.embbiosciences.com). STATS is of particular interest as it transcribes the 
suppressor of cytokine signalling (SOCS) molecule SOCSS, this is discussed in 
greater detail in section 1.6.
1.4 G-CSF and GM-CSF receptors
Hematopoeitic cytokines bind to members of the cytokine receptor superfamily, a 
large group of transmembrane proteins that share several structural featm*es. Most 
cytokine receptors are characterised by a 200 amino acid region with 4 positionally 
conserved Cys residues and a signature WSXWS motif (where W=Tip, S=Ser and 
X=any amino acid) in the extracellular domain {Wells et al, 1996). The cytoplasmic 
domains of the receptor subunits are involved in signal transduction and exhibit 
limited homology in the membrane-proximal region. This region is often refeiTed to 
as the Box-l/Box-2 motif and is essential for mitogenic signalling {Smithgall, 1998).
1.4.1 G-CSF receptor -  structure
The G-CSFR is a member of the type I cytokine receptor subfamily and binds its 
ligand with high affinity. The G-CSFR does not have intrinsic tyrosine kinase activity 
and therefore relies on cytoplasmic enzymes for the stimulation of downstream
signalling events. The G-CSFR can be found on a variety of cells including 
monocytes, mature platelets and various non-hematopoietic cells and tissues {Barreda 
et al, 2004). However, it is primarily expressed in neutrophilic progenitors and 
mature neutrophils where it functions first and foremost to transmit signals for 
proliferation, differentiation and survival of these cells (Barreda et al, 2004).
Five forms of G-CSFR exists generated through alternative splicing (class I-V), class 
I being the most predominant (Kasper et al, 1999). Structurally, this receptor consists 
of a single chain type I transmembrane molecule which contains 604 amino acids in 
the extracellular region, 26 amino acids in the transmembrane region, and 183 amino 
acids in the intracellular region (Kasper et al, 1999) The extracellular portion of the 
receptor contains 6 stmctural domains which are extensively glycosylated at nine 
potential N-glycosylation sites. It also contains 19 conserved cysteine residues that 
appear to mediate the formation of 8 disulphide bonds (Barreda et al, 2004). From 
the amino terminus, there is an immunoglobulin-like (Ig-like) domain, a cytokine 
receptor homology (CRH) module with four conserved cysteine residues and a 
WSXWS motif that are essential for ligand binding, and three fibronectin type III (FN 
III) domains (Anaguchi et a/., 1995). The cytoplasmic domain contains two closely 
conserved Box 1 and Box 2 regions of sequence homology with other cytokine 
receptors. This region appears to be essential for signal transduction of mitogenic and 
proliferative signals (Barreda et al, 2004). Additionally, a membrane distal domain, 
Box 3, contains a STAT3 binding site and appears to be essential for signal 
transduction of cellular differentiation signals (Ziegler et al, 1993). All five splice 
variants share identical extracellular domains but differ in their C-terminal sequence 
(Akbarzadeh et al, 2001).Figure 1.3
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Figure 1.3 Schematic diagram o f the G-CSFR. (Avalos., 1996)
1.4.2 G-CSF - signal transduction
Following G-CSF binding, there is homodimeristion of the receptor chains resulting 
in the formation of a tetrameric complex containing two ligand and two receptor 
molecules. Oligomerization of the receptor chains leads to rapid phosphoiylation of 
four tyrosines in the cytoplasmic region of the human G-CSFR (Y704, Y729, Y744 
and Y764) {Fukunaga et al, 1991). These phosphorylated residues subsequently 
serve as docking sites for SFI2 or phosphotyrosine binding (PTB) domains found in a 
variety of intracellular proteins {Nicholson et al, 1994). Specifically, JAKl, JAK2, 
Tyk2 and the Src kinases p55*^ and p5 6 / 5 are recruited to the receptor where they 
become activated. This in turn, leads to phosphorylation and activation of STATl, 
STATS, and STAT5 as well as the p2T'‘^ 7Raf/ERK pathway (Akbarzadeh et al, 
2001).
11
1.4.3 GM-CSFR - structure
GM-CSFR’s are expressed in low numbers (-50-500/cell) in human and murine 
macrophage, neutrophil and eosinophil lineages {Metcalf et al,. 1994), as well as 
eiythrocyte and megakaryocyte precursors, B and T foetal lymphocytes, vascular 
endothelial cells, fibroblasts, osteoblast-like cells and uterine cells {Jubinsky et al, 
1994). Receptor activation leads to proliferation, differentiation and activation of the 
heamatopoietic cells, an effect most predominant in the neutrophil and macrophage 
lineage {Rasko et al, 1997).
The GM-CSFR is a member of the gpl40 family of type I cytokine receptor group 
{Barreda et al, 2004) and is composed of two distinct chains, a  and p. Splice variants 
exist for both the a - and P- chains {Smithgall et al, 1998). The most predominant a- 
chain consists of a 298 amino acid extracellular domain, 26 amino acid 
transmembrane domain, and a short cytoplasmic domain of 54 amino acids {Nicola., 
1991) The extracellular domain contains a 100 amino acidN-tenninal region followed 
by a cytokine receptor domain containing four conserved cysteine residues and a 
WSXWS motif common to other members of the receptor family {Nicola., 1991). The 
extracellular domain also contains 11 potential N-glycosylation sites which are 
necessary for both ligand binding and signal pathway initiation {Ding et al, 1995).
Two isoforms of the human pc-chain have been identified, the most predominant 
being a full length transcript 880 amino acids long, possessing three potential N- 
glycosidation sites {Hayashida et al 1990). The pc- chain can be subdivided into a 
200 amino acid extracellular domain that contains four highly conserved cysteine
12
residues in the membrane-distal portion of the domain and a WSXWS motif in the 
membrane-proximal region. A single transmembrane domain links the extracellular 
portion to the 432 amino acid sequence of the cytoplasmic domain {Rasko et 
al,.1997).
The membrane proximal domain of the pc chain binds members of the JAK family 
and is essential for the induction of STAT5, cmyc, pim-1, and cis {Sato et al, 1993). 
The membrane distal region domains appear to be responsible for the major tyrosine 
phosphorylation of proteins that ultimately promotes c-fos and c-jun transcription, the 
induction of the Shc-Ras-ERK and phosphatidylinositol 3-kinase (PI3K) pathways, 
and prevention of apoptosis {Sakamaki et al, 1992). Membrane distal regions have 
also been implicated in the induction of differentiation and the negative regulation of 
receptor activation {Nicola., 1991).
The a-chain constitutes the main chain responsible for initially binding GM-CSF but 
does do with low affinity {Shanafelt et al, 1992). Although the pc chain is not 
involved directly with GM-CSF binding, it plays an essential role in mediating high 
affinity binding of GM-CSF to the receptor by forming a complex with the a-chain. 
{Park et al, 1992). Figure 1.4
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Figure 1.4 Schematic diagram o f  the GM-CSFR. The extracellular domain (E) 
contains a membrane proximal WSXWS motif (yellow) and a homology module 
containing 2 fibronectin type III domains with paired cysteine residues (solid black 
lines). The pcE domain is similar but larger, with 2 homology modules and 2 pairs o f  
cysteine residues. The transmembrane domain o f each receptor is blue. The white 
boxes represent Box I and Box2 JAK binding sites. (Shearer et at. 2003)
1.4.4 GM-CSFR - signal transduction
As has been discussed, GM-CSF initially binds the with low affinity to the a  chain of  
the GM-CSFR which then leads to a high affinity binding state following formation of  
the a-/pc-subunit complex. When this complex is formed, a conformational change 
occurs resulting in activation o f the receptor {Woodcock et a i, 1999).
The a- or p- subunit cytoplasmic domains do not possess any intrinsic enzymatic 
activity therefore all downstream signalling events require the association of 
cytoplasmic proteins with tyrosine kinase activity, including JAKs {O'Andrea et a i,
2000). The exact mechanism by which JAKs are activated following receptor 
oligomerization is undefined. However, it is speculated that JAKs constitutively 
associate with the Box-1 membrane-proximal region of the receptors cytoplasmic
14
domain resulting in trans-phosphorylation, a process augmented following formation 
of the ligand receptor complex {D'Andrea et al., 2000).
The activated JAKs, predominantly JAK2, proceed to initiate tyrosine 
phosphorylation of specific receptor cytoplasmic domain residues. This provides 
docking sites for a variety of Src homology (SH2) domain-containing proteins, 
including the cytoplasmic signalling proteins She and STATs activate further 
downstream signalling cascades {Itoh et al, 1998).
1.5 Negative regulation of G-CSF and GM-CSF signalling
Current literature focuses mainly on the negative regulatory pathways involved in G- 
CSF receptor binding and it appears relatively little research has focused on specific 
mechanisms involved in attenuation of the GM-CSF receptor signal. However, 
common to events involved in down-regulation of signalling from both receptors is 
involvement of a family of signalling proteins named “suppressors of cytokine 
signalling'' or “SOCS”.
1.6 SOCS
SOCS proteins are STAT-sensitive gene products which are induced as part of the 
cellular response to cytokine stimulation and are thought to act within a classical 
negative feedback loop to both inhibit activation of signalling pathways and target 
signalling components for proteasomal degradation (Zhang, et al, 1999). The 
classical inhibitory feedback mechanism of SOCS protein function is represented in 
Figure 1.5, which shows that cytokine signalling induces the expression of SOCS 
proteins through the JAK-STAT signalling pathway (Hanada et al, 2003).
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s o c s  proteins comprise a family of at least eight members which include CIS 
(cytokine induced SH2 containing protein) and SOCS1-SOCS7 {Alexander., 2002). 
All SOCS proteins have a central SH2 domain and relatively well-conserved amino 
acid sequences that form the SOCS box or CIS homology (CH) domain. SOCS I and 
SOCS3 also have unique 30 amino acid domains at the N-terminal side of the SH2 
domain, named the kinase inhibitory region (KIR) {Kubo et al., 2003). SOCS4, 
SOCS6 and SOCS7 are less well studied and are not discussed in detail here.
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Figure 1.5 Structure and function o f  SOCS proteins. Domain organisation o f SOCS 
family members.
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1.6.1 Induction of SOCS proteins
In inactivated cells SOCS proteins exist at very low, almost undetectable levels 
{Alexander., 2002). Theii* induction is dependent on cellular stimulation resulting in 
activation of the JAK/STAT pathway {Kubo et al, 2003). Many cytokines are capable 
of SOCS induction, such as G-CSF and GM-CSF described above. However, certain 
cytokines that do not signal via JAKs and a number of non-cytokine ligands can also 
induce SOCS gene expression such as TNF and LPS signalling via NF-kB and MAP 
kinase pathways {Ilangumaran et al, 2004). Thus, SOCS induction may provide a 
mechanism by which multiple stimuli can regulate cytokine receptor signalling.
It has become apparent that the STAT family of transcription factors contribute 
significantly to the transcriptional upregulation of the CIS, SOCSl and SOCS3 genes 
{Krebs et al, 2001). The promoter of CIS contains four STAT5-binding sites, all of 
which are required for eiythropoietin (Epo)-dependent activation of the CIS promoter 
in reporter assays {Matsumoto, et al, 1997). Also, the SOCSl promoter contains 
putative binding sites for STATl, STAT3 and STAT6-binding sites {Krebs et al, 
2001), Expression of S0CS3 is also ST AT-regulated, the S0CS3 promoter containing 
a single STAT1/STAT3 binding element {Krebs et al, 2002).
S0CS3 expression was also found to be increased in human leukocytes following 
treatment with a combination of interleukin-10 (IE-10) and cAMP-elevating agonists, 
including prostaglandin E% (PGE2), PGEi, forskolin, dibutryl cAMP (dbcAMP) and 
cholera toxin {Gasperini et al, 2002). PGE% and dbcAMP prolonged the stability of 
S0CS3 mRNA isloated from human leukocytes and it was shown that inhibitors of 
cAMP-dependent protein kinase A (PKA) inhibitors (H89, KT5720 and St-Ht31
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peptide) did not influence the action of PGE2 , dbcAMP and or IL-10 in the S0CS3 
signal. This implied that S0CS3 is regulated via a PKA-independent route in these 
cells {Gasperini et al, 2002). This shows cAMP-elevating agents are capable of 
SOCS3 induction and furtheimore, SOCS3 may be involved in the anti-inflammatory 
effects of cAMP-elevating di*ugs.
1.6.2 SOCS inhibition of cytokine signaling
SOCS proteins can inhibit signalling via multiple mechanisms. For example, they 
may comparatively inhibit the binding molecules to a Tyr phosphorylated receptor 
protein, thereby blocking interaction with downstream signalling proteins {Ram, et al,
2000). Alternatively, SOCSl and S0CS3 can directly inhibit JAK kinase activity 
using their extended SH2 subdomains and their kinase inhibitory regions (KIR), two 
functional domains lacking in other family members {Sasaki, et al, 1999). SOCSl 
has a high affinity for directly binding to Tyr phosphorylated JAKs, whereas S0CS3 
binds preferentially to receptor phosphor-Tyr’s {Eyckerman, et al, 2000). Another 
proposed mechanism of inhibition by SOCS involves interaction of the SOCS box 
with elongins B and C of the E3 ubiquitin ligase complex, which targets bound 
protein for proteosomal degradation {Kamura, et al, 2000). In support of this, the 
SOCS box of SOCS-1 has been shown to accelerate the ubiquitin-dependent 
proteolysis of TEL-JAK2 {Kamizono et al., 2001). It is believed that elongin-C links 
SOCS proteins and E3 ligase activity, thus targeting degradation by the proteosome 
{Johnstone et al, 2004). This has been supported by evidence that shows mutations or 
post-translational modifications of SOCSl that disrupt interaction with elongin-C 
stabilise the protein {Kamura et al, 1998).
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A dual function for SOCS has been identified in cytokine receptor signalling based on 
the interaction of SOCS3 with the Ras inhibitor pl20rasGAP {Cacalano et al, 2001). 
The result is sustained ERK signalling which inhibits cell proliferation without 
hindering cell survival (llanguraman et al, 2004).
1.6.3 SOCS3
With respect to G-CSF, current literature suggests that S0CS3 is the most likely 
candidate as a physiological regulator of cellular responses to this cytokine. Evidence 
in support of this includes studies that have shown S0CS3 is induced in primaiy 
myeloid cells stimulated with G-CSF {Hortner, et al, 2002).
G-CSF stimulation results in the specific phosphorylation of STAT3, and less 
commonly STATS and STATl {Tian, et al., 1994). Recently, hematopoietic stem 
cells extiacted from STAT3-deficient mice were found to contain trace levels of 
S0CS3 and did not show up-regulation of SOCS when stimulated with G-CSF 
(Kamezaki, et al, 2005). The same study found STAT3~null bone manow cells 
displayed a significant activation of ERK1/ERK2 phosphorylation under basal 
conditions and this level was greatly enhanced following treatment with G-CSF. 
Fui'thermore, treatment with a MEK inhibitor resulted in a marked decrease in the 
proliferation of STAT3-null cells stimulated with G-CSF {Kamezaki, et al, 2005). It 
has therefore been concluded that STAT3 functions as a negative regulator of G-CSF 
receptor signalling by inducing SOCS3 expression and that ERK activation is the 
main factor responsible for inducing the proliferative response of hematopoietic cells 
to G-CSF {Kamezaki, et al, 2005).
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S0CS3 binds selectively to phosphorylated tyrosine 729 (Y729) of the human G- 
CSFR {Hortner et al, 2002) and mutational studies have shown that Y729 regulation 
of STAT signalling is important for noimal G-CSFR function in primaiy cells 
{Hermans et al, 2002).
1.7 SOCS-independent mechanisms of inhibition of cytokine signalling 
independent of SOCS
At least two classes of inhibitors other than SOCS are known to contribute to the 
negative regulation of cytokine receptor signalling. These include protein tyrosine 
phosphatases such as SH2-domain-Tvr-phosphatase (SHP) proteins, and protein 
inhibitors of activated STATs (PIAS).
SHP proteins are constitutively expressed and are able to attenuate cytokine signal 
tiansduction by dephosphorylating signalling inteimediates such as JAKs, STATs and 
cytokine receptors (Rakesh et al 2005). There are two members of the mammalian 
SHP family, SHP-1 and SHP-2, both of which bind phosphotyrosine residues by their 
SH2 domains on a variety of cytokine receptors to inhibit signal transduction. For 
example, SHP-1 can negatively regulate cytokine signalling by dephosphorylating 
signalling components such as the interleukin-4 (IL-4) receptor (Kashiwada et al,
2001), the stem cell factor receptor c-kit (Yi et al, 1993) the erythropoeitin receptor 
(Klingmuller et al, 1995) and JAK2 {Yetter et al, 1995). SHP-1 is also capable of an 
SH2-independent interaction with the insulin receptor {Uchida et al. 1994) and with 
JAK2 {Jiao et al, 1996). In contrast SHP-2 acts mainly as a positive regulator of 
signalling {Neel et al, 2003) although some evidence argues for the existence of SHP-
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2-dependent inhibition of cytokine signalling via interaction with the gpl30 receptor 
for IL-6-family cytokines {Symes et al, 1997).
Members of the PIAS family are also constitutively expressed and attenuate signal 
transduction by suppressing STAT activity. The PIAS family contains five members, 
PIASl, PIAS3, PIASy, PIASxa and PIASxP {Chen et al, 2004). Each member of the 
PIAS family has a unique method of inhibiting STAT signalling. PIASl and PIAS3 
are known to interact directly with STATl {Chung et al, 1997) and STAT3 {Liu et 
al., 2001) respectively, thereby inhibiting STAT association with DNA. PIASx or 
PIASy do not prevent their target STAT associating with DNA and therefore must act 
by another mechanism, although this remains imdefîned. However, experiments 
earned out in pursuit of this mechanism have suggested that PIAS proteins may 
function as E3 SUMO ligase proteins which function in a manner analogous to the 
role of E3 ubiquitin ligase in ubiquitination {Johnson et al, 2001). E3 ligase activity 
has been demonstrated for all members of the PIAS family and STATs have been 
identified as a target for this activity {Johnson et al, 2001). PIASl, PIAS3 and PIASx 
all sumoylate STATl on Lys-703, close to the JAK phosphorylation site (Tyr 701), 
thereby targeting STATl for ubiquitination and terminating STAT signalling {Rogers 
et al 2003).
1.8 cAMP signalling and inflammation
Acute inflammation is defined as a short-lived inflammatory response that is localised 
to the site of tissue invasion or ti auma. In contrast, inflammation becomes pathogenic 
when it occurs at an inappropriate site, or is excessive in extent or duration. Under
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conditions of pathological stimulation, PMN bactericidal effector functions are non- 
specifically directed against the host's healthy tissue resulting in extensive collateral 
damage {Lawrence et al, 2002). It was postulated that under conditions of excessive 
collateral damage there may be accumulation o f intracellular intermediates that act to 
down-regulate the inflammatoiy response. It was further assumed that such 
extracellularly accumulated intermediates might tiigger increased intracellular levels 
of the immunosuppressive second messenger cyclic adenosine 3’,5’-monophosphate 
(cAMP), leading to inhibition of overactive immune cells {Torgersen et a l, 2002).
The A2A adenosine receptor (A2aAR) has been established as a negative regulatory 
receptor of inflammation, an effect thought to be mediated via elevation of cAMP 
levels. Studies point to existence of a physiological immunosuppressive loop in which 
disturbance of local tissue by inflammatory stimuli results in local hypoxia and the 
accumulation of exti'acellular adenosine. This in turn, acts on the A2aAR leading to 
cAMP accumulation and suppression of the immune response {Lukashev et al, 2004).
A  vast body of literature supports the anti-inflammatory effects of cAMP and as such 
there is huge interest in the pathways of induction and degradation of this nucleotide.
1.8.1 cAMP signalling systems
cAMP is a ubiquitous second messenger produced in cells in response to a variety of 
stimuli by the conversion of ATP by a family of membrane proteins called adenylyl 
cyclases (AC) {Rang et al.,2002). cAMP is inactivated by hydrolysis to 5’-AMP by
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the action of a group of enzymes called phosphodiesterases (PDEs), which seiwe an 
important role in terminating cAMP signalling in cells (Honslay et al, 2003).
cAMP is produced downstream of activated G-protein coupled receptors (GPCRs), a 
family of receptors which consist of seven transmembrane a-helieal domains. GPCRs 
transduce signals by activating heterotiimeric G-proteins, which consist of three 
subunits, a , p, y (Rang et al, 2001). The G-protein produces effects by cycling 
between inactive GDP- and active GTP-bound states. In the inactive state the G- 
protein is anchored to the membrane where it exists as an aPy complex, with GDP 
occupying the site on the a-subunit (Rang et al, 2001). Following receptor activation, 
a conformational change occurs involving the cytoplasmic domain of the receptor 
causing it to acquire high affinity for the trimeric G-protein. Association of apy with 
the activated receptor promotes GDP dissociation, allowing GTP to bind (Rang et al,
2001). This causes disruption of the trimer to release a-GTP and py-subunits; these 
are the active forms of the G-protein, which can associate with a multitude of effector 
proteins. GDP dissociation is the rate-limiting step of G-protein activation, thus 
activation is terminated when the hydrolysis of GTP to GDP occurs thiough an 
intrinsic GTPase activity of the a-subunit. The GDP bound a-subunit dissociates 
from associated effects and reforms the trimeric complex with Py to complete the 
cycle (Rang et al, 2001).
G-proteins regulate the activity of various membrane enzymes and ion channels. G- 
proteins may be stimulatory (G s) or inhibitoiy (G i). Gg-stimulated AC activity is
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responsible for production of cAMP, which in turn initiates activation of a variety of 
cellular proteins.
1.9 Intracellular cAMP sensors
cAMP has been traditionally thought to signal exclusively through cAMP-dependent 
protein kinase (PKA). However, PKA-independent actions of cAMP have been 
recognised in various experimental systems including cyclic nucleotide-gated ion 
channel activation and the exchange proteins directly activated by cAMP (Epacsl and 
2) {de Rooij, et al, 1998). All these proteins bind cAMP thiough conserved cAMP 
binding domains (Dremier et al, 2003).
1.9.1 PKA
For many years, PKA was thought to be the only intracellular target of cAMP. PKAs 
are present in most cells as two isoenzymes, PKAI and PKAII, which are tetramers 
compose of two catalytic (C) and two regulatory (RIa,p or RII a,P) subunits 
{Kopperud et al, 2003). The R subunit of PKA modulates its kinase activity indirectly 
by binding to the A-kinase anchor protein (AKAP) family (section 1.9.2). AKAPs are 
known to bind to the RII regulatoiy subunit to orchestrate activation of PKA {Michel­
et al, 2002). Each R subunit has two c AMP-binding domains (site A and site B). 
Upon binding of two cAMP molecules on both R subunits, the inactive tetramer is 
dissociated into one dimer of R subunits and two active C subunit monomers which 
can then phosphoiylate various cytoplasmic and nuclear target proteins such as cAMP 
response element binding protein (CREB) {Kopperud et al, 2003). Figure 1.6
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Figure 1.6 PKA/cAMP signaling pathway: The active C subunit phosphorylates 
CREB protein resulting in transcription.
1.9.2 AKAPs
GPCRs are capable o f stimulating a variety o f intracellular transduction pathways. 
However, its essential fidelity is maintained between each pathway in order to 
produce the correct physiological response (Michel et ai, 2002). This requires the 
accurate selection o f effector molecules for regulated activation and deactivation and 
a principle strategy in achieving this selection specificity is compartmentalization of 
signalling enzymes {Michel et a l, 2002).
AKAPs (A-kinase anchoring proteins) provide compartmentalisation o f multivalent 
signalling processes {Malbon et a l, 2004). These proteins bind to membrane bound 
GPCRs to orchestrate the interactions o f a variety o f proteins such as protein kinases
25
and protein phosphatases. For example, AKAPs bind to the regulatoiy subunit of PKA 
to direct the kinase to discrete intracellular locations {Kopperund et al, 2003). 
Recently, functional studies aimed at disrupting AKAP-PKA complexes have 
demonstrated a role for anchored PKA in various cellular processes, including gene 
transcription, hormone-mediated insulin secretion and ion-channel modulation (Alto 
et al, 2002). By binding to additional signalling molecules, AKAPs might function to 
coordinate multiple components of signal-transduction pathways {Malbon et al, 
2004).
1.9.3 Epacs
In 1998, two new cAMP receptors were identified and named Epacl and Epac2 
(exchange protein directly activated by cAMP). Epac proteins function as GEFs 
which, upon cAMP binding, specifically activate the small G-proteins Rapl and 
Rap2. Epacl and Epac2 have one and two cAMP-binding sites respectively, which are 
located in the N-terminal part of the proteins. Epacl is ubiquitously expressed and 
Epac2 is found predominantly in the brain and adrenal glands {Kawasaki, et al., 
1998).
Insights gained from stiuctural modelling studies have lead to development of an 
Epac-selective cAMP analogue called 8-(4-chloro-phenylthio)~2’-0-methyladenosine- 
3’, 5’cyclic monophosphatase or 8CPT-2-0-Me-cAMP {Enserink et al, 2002). This 
agent has allowed differentiation between Epac-dependent and PKA-dependent 
cAMP effects. Use of this selective activator has revealed that Epac’s participate in 
various aspects of cell function. For example, Epac-1 has been found to play a 
functional role in integrin-mediated cell adhesion in non-myloid cell lines {Enserink
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et al, 2004), while Epac-2 appears to be important in pancreatic (3-cell insulin granule 
exocytosis (Holz., 2004). Both Epac-1 and Epac-2 have been implicated in the 
regulation of vascular endothelial barrier function (Cullere et al, 2005).
1.10 Experimental Hypothesis
Increased levels of cAMP are able to attenuate cytokine signalling in endothelial cells 
{Sands et al, submitted for publication). Furthermore, it has been established that an 
increase in cAMP is coupled with an increase in levels of SOCS proteins, in particular 
S0CS3. What has yet to be elucidated, is whether this response occurs in other cell 
types, this aim forms the basis of this project where it is also hoped to establish the 
mechanism by which SOCS3 is induced.
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CHAPTER 2
Materials and Methods
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2.1 Chemicals and Suppliers
All reagents were of the highest grade commercially available and obtained by the 
following suppliers:
Abeam plc.(UK)
phosphoCREB antibody (#ab3419) stock Ipg/ml
BDH biochemical, Poole, England (UK)
HEPES
Biolog Life Science Institute
8 - (4-Clorophenythio)-2 ’ - O-methyl-c AMP
Calbiochem-Novabiochem (UK)
Forskolin, H89, U0126, SB 203580, Jak Inhibitor 1, MG132 
Cell Signaling technology
Statl Antibody (#9172), Phospho-Statl Antibody (#9171), Stat3 Antibody (#9132), 
Phospho-Stat3 Antibody (#9138), p44/42 MAP Kinase Antibody (#9102), Phospho- 
p44/42 MAPK Antibody (#9106), Rabbit anti-phosphoThr 180/Tyr 182-p38 Anitbody
CN Biosciences, Merck Biosciences Ltd., Beeston, Nottingham,UK
Genejuice transfection reagent
Fisher Scientific, Loughborough, Leicestershire,UK
Sodium dodecyl sulphate (SDS), methanol, ethanol, sodium flouride, concentiated 
hydrochloric acid
29
GIBCO BRL Life Technologies, Paisley, UK 
Optimem
Invitrogen, Inchinnan Business Park, Paisley, UK
Rainbow marker
Inverclyde Biologicals, Strathclyde Business park, Bellshill, Lanarkshire, UK
Protran nitrocellulose (Schleicher & Schuell), pore size: O.lpm
LGC Promochem, Middlesex, UK
HL60 cells, U937 cells
Pierce, Rockford, IL, U.S.A
Western Blot stripping solution
Perkin Elmer, Wellesley, MA, U.S.A
Enhanced chemiluminescence (ECL) solutions
Roche Molecular Biochemicals/ Boehringer-Mannheim, Mannheim, Germany
Tris [hydroxymethyl]aminomethane;(Tris)
R&D Systems, Minneapolis, MN, U.S.A
G-CSF, GM-CSF
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Santa Cruz Biotechnology Inc., Santa Cruz, CA, U.S.A
SOCS-3 antibody (#sc-7009) stock 200jLig/ml
Sigma-Aldrich Company Ltd., Poole Dorset
Soybean trypsin inhibitor, benzamidine, bovine serum albumin, thimerosal, 
bromophenol blue, N,N,N ’ ,N ’ -tetramethylethy lenediamine (TEMED), RPMI, 
Dulbecco’s modified Eagle’s medium (DMEM), trypsin, penicillin/streptomycin, L- 
glutamine, FBS, Anti-rabbit antibody (#A5420), Anti-goat antibody (#A5420), Anti­
mouse (#A4416), aciylamide/bisacrylamide, PMSF, Triton X-100, Tween-20
Whatman international Ltd., Maidstone, Kent
Filter paper (Schleicher & Schuell), Ref: 10382658
S0CS3 positive control pcDNA/myc epitope-tagged human S0CS3 constructs were 
initially prepared in-house at Queens University, Belfast U.K., by Professor Jim 
Johnson.
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2.2 Cell culture
2.2.1 Cell Maintenance
Cells were grown at 37°C in a humidified atmosphere containing 5% (v/v) COg.
Human promyelocytic HL60 and pre-monocytic U937 cells were maintained in RPMI 
medium supplemented with 10% (v/v) FBS, ImM L-glutamine, 100 units/ml 
penicillin and lOOpg/ml streptomycin. Cells were grown in suspension culture and 
maintained by replacement of medium eveiy two to three days. Cells were cultured in 
T-IOOO flasks, each flask containg 25ml of cell suspension. Cells were split by 
removing 20ml of cell suspension and replacing this with 20 ml fresh RPMI.
Human embryonic kidney 293 cells ( HEK 293) cells were maintained in DMEM 
supplimented with 10% (v/v) FBS, ImM L-glutamine, 100 units/ml penicillin and 
lOOpg/ml streptomycin. Cells reached confluence every two to three days. Confluent 
monolayers of cells were washed thoroughly with 5ml PBS before being treated with 
1ml trypsin. Cells were exposed to trypsin for up to 30 seconds before the flask was 
shaken to lift the monolayer of adherent cells from the base of the flask. 9ml of fresh 
DMEM was added to the flask to neutralise the trypsin. 9ml of this suspension was 
then removed and replaced with fresh trypsin resulting in a 1 in 10 dilution of cells.
2.3 Counting cells
HL60 and U937 cells were counted and plated onto a 6-well plate on the day of each 
stimulation. Ix 10  ^cells were required per well of a 6-well plate for each stimulation. 
Cells were counted using the haemocytometer method to estimate the cell population 
in each flask. The volume of suspension extracted ftom each flask varied daily
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according to cell confluence. Once removed, the cell suspension was centrifuged at a 
speed of lOOg for 2mins. The supernatent media was removed and replaced with 1ml 
fresh RPMI per 1x10^ cells. Cells were then plated on to a 6 well plate at 1ml per 
well.
2.4 Transient expression of SOCS3 in HEK 293 cells
Genejuice was used a the transfection agent to transfect pcDNA3/myc epitope-tagged 
human S0CS3 into HEK 293 cells. For a 6-well plate, DNA was transfected at a 
concentration of 2pg/well. 1.2ml Optimem was placed into a sterile microfiige tube 
with 7pi Gene Juice, vortexed and left to incubate for 5 minutes. 2pl of S0CS3 
plasmid DNA (pCDNA/Flag-SOCS-3) was then added to the microfuge tube, the tube 
was vortexed briefly and left to incubate for 15min at room temperature. 200pi of the 
DNA-Genejuice mix was then added to each well containing 1ml of fresh medium 
and left to incubate overnight. Medium was replaced 24hr post-transfection and cells 
used after a further 24 hours.
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2.5 Cell Stimulations
Undifferentiated U937 or HL60 cells were used for stimulations, Eveiy stimulation 
experiment was carried out in a 6 well plate containing 1ml of cells at a concentration 
of 1x10*^  per well. The agents used were as follows:
Figure 2.1 Table o f Treatments o f monolytic cell lines
AGENT CONCENTRATION INCUBATION PERIOD
Rolipram lOpM 6hr
Forskolin lOpM 6hr
H89 5pM 6hr or 15min
6Be 50pM 6hr or 15min
8P-CPT O.lmM 6hr or 15 min
G-CSF lOng/ml 30min
GM-CSF lOng/ml 30min
SB lOmM Pre-treat 30min + 6hr
U0126 IpM Pre-treat 30min + 6hr
Jak inhibitor 1 0.5pM Pre-ti*eat 30min + 6hr
MG132 3pM Pre-treat 30min
2.5.1 Preparation of cell lysates
At the end of the stimulation period, 6 well plates were placed on ice to terminate the 
reaction. The well contents were then transfeired directly into cooled, sterile 
microfuge tubes and centrifuged at 8000g for 30secs. The excess media was removed 
and the pellet washed in ice-cold PBS before being centrifuged at 40,000g for 30secs,
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this step was repeated to eiisiiie all media was washed off. Following the second 
wash, the pellet was solubilised in 50pl RIPA (50mM sodium Hepes (pH7.5), 1% 
(v/v)Triton X-100, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS, 0.15M sodium 
chloride, 5mM EDTA, lOmM sodium flouride, lOmM sodium phosphate, lOpg/ml 
soybean trypsin inhibitor, lOpg/ml benzamidine, O.lmM PMSF and 0.02% (w/v) 
protease inhibitor cocktail). The lysate was centrifuged at 40,000g for 15 min and the 
supernatent transferred into sterile microfuge tubes and frozen at -80°C. The samples 
were defrosted for protein normalisation and immunoblotting as described in section
2.5.1 and 2.5.2.
2.5.2 Protein normalisation by Bicinclioninic acid (BCA) protein assay 
Duplicate 0.01ml samples of known BSA standards in the range of 0-2 mg/ml, along 
with unknown protein samples were loaded onto 96-well plate. 0.2ml BCA solution ( 
1% (w/v) 4,4 dicarboxy-2,2 biquinolone disodium salt, 2% (w/v) sodium carbonate, 
0.16% (w/v) sodium potassium tartrate, 0.4% (w/v) copper (II) sulphate) were added 
to each well. A protein concentration-dependent reduction of Cu^ '^ to Cu" was 
indicated by a colour change from green to purple. This is quantified by measuring 
absorbance at 492nm. The colour- was left to develop for 15 min before absorbance of 
the standards was measured and used to plot a best-fit straight line from which the 
unknown protein samples were calculated using Revelation software run by a PC 
linked to a platereader.
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2.6 Laboratory techniques
2.6.1 SDS-PAGE and immunoblotting
Samples prepared for SDS-PAGE were equalised for protein using the bicinchoninic 
acid assay described in Section 2.5.3. Pre-stained protein markers (Invitrogen 
Rainbow Markers, range 6.5-175kDa) in sample buffer (50mM Tris-HCl (pH 6.8), 
10% (v/v) glycerol, 12% (w/v) SDS, 0.0001% (w/v) bromophenol blue, ImM DTT) 
were also prepared in electrophoresis sample buffer to estimate protein molecular 
mass.
40pi of sample was equalised for protein content and subsequently subjected to 
discontinuous SDS-PAGE using a 6 cm 10% (w/v) polyacrylamide resolving gel 
(10% (w/v) acrylamide, 0.3% (w/v) bisacrylamide, 0.4M Tris (pHB.8), 0.1% (w/v) 
SDS, 3% (v/v) glycerol, 0.01% (w/v) ammonium persulphate and 0.001% (v/v) 
TEMED) and a 2cm 3% (w/v) stacking gel (3% (v/v) acrylamide, 0.1% (v/v) 
bisacrylamide, O.IM Tris (pH 6.8), 0.1% (w/v) SDS, 0,01% (w/v) ammonium 
persulphate and 0.0001% (v/v) TEMED). Electrophoresis was carried out using 
Biorad Mini Protean II or 111 gel electrophoresis systems in running buffer (27.4mM 
Tris, 0.1 OM glycine, 0.1% (w/v) SDS) at 150V until the bromophenol blue dye 
reached the end of the gel. Proteins electrophoretically ti’ansferred from the gel onto a 
niti'ocellulose membrane at 400mA for 45mins in transfer buffer (24.7mM Tris, 
0.19M glycine in 20% (v/v) methanol). The nitrocellulose membrane was then neatly 
trimmed and rinsed briefly in PBS before blocking for Ihr at room temperature in 
Blotto (5% (w/v) skimmed milk, 0.2% (v/v) Tween in PBS). The membrane was then 
washed again in PBS before being placed into a plastic envelope with 2ml Blotto 
containing a 1:1000 dilution of primary antibody. Depending on the primary used, the 
blot was either be incubated overnight at 4°C in the cold room, or at room temp for
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Ihr on a rotating platform Table 2.2. The membrane was then rinsed briefly in PBS 
and washed three times, at 10 min intervals in Blotto. After the final Blotto wash, the 
membrane was rinsed in PBS and transferred into an envelope containing 2ml Blotto 
and a 1:1000 dilution of the relevant HRP-conjugated secondary antibody. This was 
placed on a rotating platform for Ihr at room temperature. The membrane was then 
removed form the envelope, rinsed in PBS and washed for two lOmin washed in 
Blotto, followed by two 10 min washed in PBS. Membranes were then exposed to an 
enhanced chemiluminescence (ECL) development procedure. HRP-specific oxidative 
degeneration of luminal caused emission of light at 428nm, detected by Kodak X- 
OMAT Blue X-ray film, thereby allowing visualisation of immunoreactive proteins.
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Table 2.2 Antibody incubation conditions
INCUBATION CONDITIONS BLOTTOPROTEIN
1°AB 2°AB l-AB 2°AB
SOCS3 S0CS3 1:1000 
Ihr, room temp
Anti-Goat HRP 
1:1000 
Ihr, room temp
5% skimmed milk 
PBS TWEEN PBS TWEEN
P-CREB P-CREB 1:1000 
Overnight, cold 
room
Anti-RabbbitHRP 
1:1000 
Ihr, room temp
1%BSA
TBST
5%MILK TBST
ERK ERK 1:1000 
Overnight, cold 
room
Anti-Rabbbit HRP 
1:1000 
Ihr, room temp
1% BSA 
TBST
5%MILK TBST
P-ERK P-ERK 1:1000 
Overnight, cold 
room
Anti-mouse HRP 
1:1000 
Ihr, room temp
1% BSA 
TBST
5%MILKTBST
STATl STATl 1:1000 
Overnight, cold 
room
Anti-Rabbbit HRP 
1:1000 
Ihr, room temp
1%BSA
TBST
5%MILK TBST
P-STATl P-STATl 1:1000 
Overnight, cold 
room
Anti-Rabbbit HRP 
1:1000 
Ihr, room temp
1%BSA
TBST
5%MILK TBST
STAT3 STAT3 1:1000 
Overnight, cold 
room
Anti-Rabbbit HRP 
1:1000 
Ihr, room temp
1% BSA 
TBST
5%MILK TBST
P-STAT3 P-STAT3 1:1000 
Overnight, cold 
room
Anti-mouse HRP 
1:1000 
Ihr, room temp
1%BSA
TBST
5%MILK TBST
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2.6.2 Stripping nitrocellulose membranes for re-probing
The membrane was rinsed in PBS to remove traces of ECL solution, then placed in a 
plastic envelope containing 2ml Western Blot stripping solution. This was placed on a 
rotating platform and incubated for 30min at room temperature. At the end of this 
incubation, the membrane was removed from the enveloped, rinsed in PBS and 
developed using the ECL method described in 2.5.2. To ensure the membrane was 
stripped of all immunoreactive antibodies. The membrane was then rinsed in PBS 
and blocked in Blotto for Ihr. After this time, the membrane was rinsed in PBS and 
placed in an envelope containing 2ml Blotto and a 1:1000 dilution of the relevant 
primary antibody as described in 2.5.2.
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Statistical Analysis
Non-saturating exposures of all immunoblots were analysed using Totallab v2.0 
imaging analysis software (purchased from Phoretix, UK).
Statistical analyisis was performed using GraphPad Prism V4.0. One-sample t-tests 
were perfoimed to determine whether there was a statistically significant difference 
between mean densitometry readings under various experimental conditions. Mean 
densitometiy was calculated for n=3 for each experimental parameter compared Eg. 
Average of n=3 densitometiy reading for treated Vs. Average of n==3 densitometry 
reading for untreated cells.
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CHAPTER 3
RESULTS
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3.1 Introduction
SOCS3 induction can occur via activation if several signalling mechanisms, the most 
extensively documented route being the JAK/STAT pathway (section 1.6.1). 
However, a correlation has also been found between elevated levels of cAMP and 
increased S0CS3 expression. Recent work has shown a link exists between increased 
levels of cAMP and SOCS3 in vascular endothelial cells leading to a decrease in 
cytokine signalling {Sands et al, submitted for publication). Since cAMP is a potent 
anti-inflammatory second messenger in many cells, it is desirable to investigate 
whether this phenomenon is manifested in other cell types. Thus, the main aim of this 
project is to establish whether cAMP elevation can induce SOCS3 expression in two 
myeloid cell lines and examine the possible mechanism(s) responsible for this 
induction as well as the functional consequences for cytokine signalling.
3.2 Results
In order to achieve a more detailed insight into the relationship between increased 
cAMP and S0CS3, the effects of forskolin (Fsk), an efficacious activator of adenylate 
cyclase catalytic units, on the activation of SOCS3 protein were investigated. Based 
on previous literature, Fsk is capable of SOCS3 induction in human neutrophils and 
PBMC when used in conjunction with IL-10 (section 1.6.1). However, the ability of 
Fsk alone to induce SOCS3 in myeloid cell lines has yet to be ascertained. To 
investigate this further time courses and concentration dependence were examined to 
establish the optimal effects of Fsk on naïve U937 histocytic lymophocytes and FIL60 
promyelocytic leukaemia cells. Rolipram, a Phosphodiesterase 4 inhibitor, was added 
to prevent breakdown of cAMP (Figures 3.1-3.2)
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Figure 3.1 Time course of Fsk induction of SOCS3 expression in U937 cells
U937 cells were treated with Fsk [lOjiiM] at a range of time points 
(n=3). Cell lysate was extracted and prepared according to section 2.4.1 
and the protein content equalised prior to SDS-PAGE hactionation. 
The proteins were subsequently transferred onto nitro-cellulose and 
probed using a SOCS3 antibody. The results show there is a time- 
dependent increase in SOCS3 expression in U937 cells and that 
maximum expression occurs at 61us. Lysate from IL-6 [lOOng/ml] 
stimulated cells was loaded as a comparison although no S0CS3 
protein was expressed. Extract horn HEK 293 cells expressing Flag- 
SOCS3 was used as a positive control for the blot.
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Figure 3.2 Time course of Fsk induction of SOCS3 expression in HL60 cells
HL60 cells were treated with Fsk [lOpM] at a range o f time points 
(n=3). Cell lysate was extracted and prepared according to section
2.4.1 and the protein content equalised prior to SDS-PAGE 
fractionation. The proteins were subsequently transferred onto nitro­
cellulose and probed using a SOCS3 antibody. The results show there 
is a time dependent increase in SOCS3 expression in HL60 cells and 
that maximum expression occurs at 6hrs. Lysate from IL-6 [lOOng/ml]- 
stimulated cells was loaded as a comparison although no SOCS3 
protein was expressed. Extract from HEK 293 cells expressing Flag- 
S0CS3 was used as a positive control for the blot.
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Figure 3.1 and 3.2 shows that SOCS3 expression does not plateaux at this 61ii' time 
point in either U937 or HL60 cells. This suggests that maximal expression may occur 
beyond the 6hr stimulation. It has been shown that both HL60 and U937 cells express 
S0CS3 in response to a 6hi’ treatment with Fsk [lOpM]. It has also been demonstrated 
that S0CS3 protein was not detected in cell extract treated from U937 and HL60 cells 
treated with IL-6 for 6hr (scan densitometiy Figme 3.1-3.2). This may be due to the 
fact that IL-6 induction of SOCS3 occurs transiently at a lower time point, or that 
SOCS3 induction by IL-6 occurs sometime after the 6hr incubation. HEK293 extract 
expressing Flag S0CS3 acted as an effective positive control, as huge level of S0CS3 
protein was detected. A 61ir Fsk exposure time was used for subsequent concentration 
dependence analysis of S0CS3 induction in U937 and HL60 cells.
For the purpose of this investigation, it was essential to establish the time point at 
which S0CS3 is significantly induced. This was deteimined by obseiwing 
concentiation dependence of Fsk-induced SOCS3 expression in U937 and HL60 cells 
(Figures 3.3-3.4).
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Figure 3.3 Concentration dependence of Fsk-induced SOCS3 expression in 
U937 cells. Undifferentiated U937 cells in a 6-well plate were treated 
with a range o f Fsk concentrations for 6hrs (n=3). Cell lysate was 
extracted and prepared according to section 2.4.1 and the protein 
content equalised prior to SDS-PAGE fractionation. The proteins were 
subsequently transferred onto nitro-cellulose and probed using a 
SOCS3 antibody. The graph shows there was a concentration- 
dependent increase in SOCS3 expression when cells are exposed to 
Fsk for 6hrs and maximum induction of SOCS3 was achieved at 
lOpM.
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Figure 3.4 Concentration dependence of Fsk-induced SOCS3 expression in 
HL60 cells. Undifferentiated HL60 cells in a 6-well plate were treated 
with a range o f concentrations o f Fsk for 6hrs (n=3). Cell lysate was 
extracted and prepared according to section 2.4.1 and the protein 
content equalised prior to SDS-PAGE fractionation. The proteins were 
subsequently transferred onto nitro-cellulose and probed using a 
SOCS3 antibody. As with U937 cells, there was a concentration- 
dependent increase in SOCS3 expression. The maximum expression of 
SOCS3 was achieved at a concentration o f lOpM.
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S0CS3 protein is subject to rapid turnover in many cell types via proteolysis. This is 
attributed to the interaction of the conserved SOCS-box domain with Elongins B and 
C that form part of the ubiquitin ligase complex {Zhang et al, 1999) which 
ubiquitinates and targets associated proteins, and SOCS proteins themselves, for 
degradation {Krebs et al, 2001). It was therefore appropriate to ensure the S0CS3 
signal was not subject to degradation. Both cell lines were treated with Fsk [lOpM] in 
the presence of proteasome inhibitor (MG 132) at a range of time points. MG 132 
reduces degradation of ubiquitin conjugated proteins by disrupting proteasomal 
interaction with elongin B/C of the S0CS3 protein. The results of these experiments 
are represented in Figures 3.5 and 3.6.
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Figure 3.5 Effect of proteosome inhibitor 1VIG132 on Fsk-induced SOCS3 
expression in U937 cells. U937 cells in a 6-well plate were treated 
with Fsk [lOpM] for 6hrs both in presence and absence o f MG132 
[3pM] (n=3). Cell lysate was extracted and prepared according to 
section 2.4.1 and the protein content equalised prior to SDS-PAGE 
fractionation. The proteins were subsequently transferred onto nitro­
cellulose and probed using a SOCS3 antibody. Flag-S0CS3 was 
loaded as a positive control. The 6hr time point appeared to produce 
the strongest SOCS3 signal. When the average densitometry 
measurement o f SOCS3 at 6hrs in cells treated with Fsk+MG-132 was 
compared to cells treated with Fsk alone a p value of 0.07 was 
obtained. Thus, treating U937 cells with MG 132 does not significantly 
increase the level o f SOCS3 induction.
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Figure 3.6 Effect of proteasome inhibitor MG132 on Fsk-induced SOCS3 
expression in HL60 cells. HL60 cells in a 6-well were treated with 
Fsk [lOpM] for 6hrs both in presence and absence o f MG 132 [3pM] 
(n=3). Cell lysate was extracted and prepared according to section
2.4.1 and the protein content equalised prior to SDS-PAGE 
fractionation. The proteins were subsequently transferred onto nitro­
cellulose and probed using a SOCS3 antibody. The 6hr time point 
appeared to produce the strongest SOCS3 signal. When the average 
densitometry measurement o f SOCS3 at 6hrs in cells treated with 
Fsk+MG-132 was compared to cells treated with Fsk alone a p value 
o f 0.1912 was obtained. Thus, treating HL60 cells with MG 132 does 
not significantly increase the level o f SOCS3 induction.
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MG132 did not significantly increase SOCS3 expression in U937 or HL60 cells. This 
suggests that at S0CS3 is not subject to proteasomal degradation in these cell lines 
following a 6hr treatment with Fsk. Based on these results, MG 132 was not used in 
any other stimulations. Both cell types produced the same pattern of results for both 
time course and concentration response experiments, however, from this stage it was 
decided to proceed with U937 cells only. This decision was made based on the fact 
that U937 cells were capable of inducing S0CS3 expression to greater extent than 
HL60 cells, as determined by comparison to the SOCS3 positive control run on each 
gel.
SOCS proteins may be induced by multiple stimuli, not just activators of the 
JAK/STAT pathway. An efficacious inducer of SOCS3 is lipoplysaccharide (LPS), a 
component of the outer cell wall of Gram-negative bacteria (Bode et a l, 2003). LPS 
stimulates the TLR4 signalling system to activate intracellular messengers such as 
NFkB and ERK (Bode et a l, 2003). ERK, as has been discussed, is capable of 
indirect induction of SOCS3 by phosphorylating STAT3 (1.3.2). It is therefore 
important to demonstrate any positive S0CS3 response was due solely to the effects 
of forskolin and not bacterial contamination of stock solution. In order to eliminate 
the effects of LPS contamination on the level of S0CS3, cells treated with and 
without Fsk were placed in media containing filter-sterilised polymyxin-B as a 
conti'ol Polymixin B is a bacteriopeptide that binds LPS, thus neutralising its 
biological effects. The results of this experiment are shown in Figure 3.7.
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Figure 3.7 Effect of polymyxin B on Fsk-induced SOCS3 expression.
U937 cells in a 6-well plate were exposed to Fsk [lOpM] for 6hrs both 
in the presence and absence o f Polymyxin B (P) [Ipg/ml] (n=3). Cell 
lysate was extracted and prepared according to section 2.4.1 and the 
protein content equalised prior to SDS-PAGE fractionation. The 
proteins were subsequently transferred onto nitro-cellulose and probed 
using a SOCS3 antibody. A one-sample t-test was performed to 
compare the level o f SOCS3 in cells treated with Fsk Vs 
Fsk+Polymixin B. A p value o f 0.2219 was obtained which confirmed 
there was no statistically significant difference in levels of SOCS3 
induced in cells treated with Fsk + Polymixin B Vs. Fsk alone. 
Untreated cells and cells treated with Polymixin B alone were used as 
controls.
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There was no statistically significant difference in the level of SOCS3 between cells 
bathed in Polymixin B media versus polymyxin B- free media. Thus, SOCS3 
induction is due solely to Fsk treatment and not due to any bacterial contamination.
3.3 G-CSF and GM-CSF signalling pathways
G-CSF and GM-CSF receptor signalling pathways were chosen to test the functional 
significance of S0CS3 induction. G-CSFR interaction with S0CS3 has been well 
documented {van de Geijin et al, 2004) and due to functional similarities of the GM- 
CSFR, it was decided to investigate the functional consequences of SOCS3 induction 
of the signalling pathways of both receptors.
The literature states that the G-CSFR signals through STATl, STAT3, STAT5 as well 
as the Ras/RafERK pathway. In contrast, the GM-CSFR transduction pathway is less 
well documented. It was hypothesised that both the G-CSFR and GM-CSFR would be 
capable of S0CS3 induction via STAT activation and that in turn, S0CS3 induction 
would have a negative feedback mechanism to diminish the level of STAT 
phosphorylation by each receptor, since STAT activation by SOCS3-targeted 
receptors should be reduced.
Initially it was important to verify that the JAK/STAT signalling pathway was 
engaged in U937 cells in response to treatment with G-CSF and GM-CSF. 
Furthermore, it was hoped to establish if elevated levels of cAMP were capable of 
diminishing the G-CSF/GM-CSF induced signal thereby inhibiting cytokine 
signalling.
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U937 cells were exposed to G-CSF and levels o f STAT 1, STAT 3 and ERK 1,2 were 
measured. The results are shown in Figures 3.8-3.10.
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Figure 3.8 Time course of G-CSF-induced STATl phosphorylation in U937 
cells. U937 cells were treated with G-CSF [lOng/ml] at a range o f time 
points (n=3). Cell lysates were then prepared as described in section 
2.4.1 before protein content o f each sample was equalised prior to 
fractionation by SDS-PAGE. The proteins were then transferred to 
nitro cellulose and subject to immunoblotting with total STATl and 
phospho-Tyr701- STATl antibodies. STAT 1 was first detectable 
after 5mins, maximal STATl phosphorylation is achieved after 15min 
and this response is sustained for the duration o f the time course.
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Figure 3.9 Time course of G-CSF-induced STAT3 phosphorylation in U937 
cells. U937 cells were treated with G-CSF [lOng/ml] for a range o f 
time points (n=3). Cell lysates were prepared according to section 2.4.1 
and equalised for protein content before being subject to fractionation 
by SDS-PAGE. Proteins were then transferred to nitro-cellulose and 
immunoblotting was performed using total STAT3 and phospho- 
Tyr705-STAT3 antibodies. The blot and graph show that STAT3 is 
strongly phoshporylated after 5mins and this is sustained remaining 
time points.
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Figure 3.10 Time course G-CSF-induced ERK1,2 phosphorylation in U937 
cells. This U937 cells were treated with G-CSF for a range o f time 
points (n=3). Cell lysates were prepared according to section 2.4.1 and 
the protein content o f each sample equalised before being subject to 
SDS-PAGE fractionation. The proteins were then transferred to nitro­
cellulose and immunoblotting was performed using total ERK and 
phospho-Thr202,Tyr204-ERKl,2 antibodies. ERK phosphorylation 
was detectable at 5mins and maximal level o f phosphorylation noted at 
15min, this is sustained for the remainder o f the time course.
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In a second set o f stimulations, U937 cells were exposed to GM-CSF. As with 
G-CSF, levels o f STAT 1, STAT 3 and ERK 1,2 were measured. The results are 
shown in Figures 3.11-3.13.
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Figure 3.11 Time course of GM-CSF-induced STATl phosphorylation in U937 
cells. U937 cells were treated with GM-CSF for a range o f time points 
(n=3). Cells lysates were prepared as described in 2.4.1 and the protein 
content o f each sample equalised prior to fractionation by SDS-PAGE. 
The proteins were transferred onto nitro-cellulose and probed for total 
STATl and phospho-Tyr701- STATl antibodies. STATl is transiently 
phosphoryated at 15min.
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Figure 3.12 Time course GM-CSF-induced STAT3 phosphorylation in U937 
cells. U937 cells were treated with GM-CSF [lOng/ml] for a range o f  
time points (n=3). Cell lysates were prepared according to section 
2.4.1. and equalised for protein content prior to fractionation by SDS- 
PAGE. Proteins were then transferred to nitro-cellulose followed by 
immunoblotting with total STAT3 and phospho-Tyr705-STAT3 
antibodies. STAT3 phosphorylation is a transient event, maximal at 
15min, at which point the level o f STAT3 phosphorylation appears to 
diminish. G-CSF was loaded for comparison purposes, it shows that G- 
CSF stimulated cells produce a greater level o f STAT3 
phosphorylation than GM-CSF stimulated cells.
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Figure 3.13 Time course of GM-CSF-induced ERK1,2 phosphorylation in 
U937 cells. U937 cells were treated with GM-CSF for a range o f time 
points (n=3). Cell lysates were prepared according to section 2.4.1 and 
protein content equalised prior to fractionation by SDS-PAGE. The 
proteins were transferred to nitrocellulose followed by immunoblotting 
with total ERK and phospho-Thr202,Tyr204-ERKl,2 antibodies. The 
blot shows that ERK 1,2 phosphorylation is a transient event peaking at 
15min, it is also detected at 30min. G-CSF was loaded for comparison 
purposes, it shows that G-CSF stimulated cells produce a greater level 
of ERK phorsphorylation than GM-CSF stimulated cells.
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From these experiments, it can be concluded that both G-CSF and GM-CSF activate 
the JAK/STAT pathways in U937 cells. However, there were several distinct aspects 
about the responses to each cytokine. For example, in U937 cells treated with G-CSF, 
phosphorylation of STATl, STAT3 and ERK 1,2 was achieved at 15min and that this 
level of phosphorylation was sustained for up to 1 hour. In conti'ast, in U937 cells 
treated with GM-CSF, STATl was phosphorylated markedly transient at 15min. 
Similarly, phoshpoiylation of STAT3 and ERK 1,2 in response to GM-CSF peaked at 
15min and diminished over the remainder of the time course. Therefore, U937 cells 
produce optimal phosphorylation of STATl, STAT3 and ERK 1,2 following a 15min 
treatment with G-CSF or GM-CSF and this signal is sustained for up to 60mins.
3.5 Effects of elevated cAMP on G-CSF and GM-CSF signalling
It has been shown that elevated levels of cAMP are able to induce SOCS3. Previous 
literature states that SOCS proteins have a role in G-CSF and GM-CSF signalling 
(Barreda et al., 2004). More specifically, SOCS3 has been implicated in attenuation of 
the G-CSFR signalling pathway {van de Geijin et al, 2004), although the specific 
SOCS protein(s) involved in GM-CSFR signalling have yet to be elucidated. 
Therefore, it was decided to test the effects of increased cAMP on S0CS3 induction 
in G-CSF-stimulated cells and compare these effects with GM-CSF-stimulated cells. 
To investigate the effects of elevated cAMP on G-CSF and GM-CSF signalling, U937 
cells were treated with forskolin in combination with either G-CSF or GM-CSF for 
30min before S0CS3 levels were measured. The results of these experiments are 
illustrated by figures 3.14 and 3.15.
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Figure 3.14 Effect of Fsk-pre-treatment on G-CSF/GM-CSF induced STAT3 
phosphorylation. U937 cells were plated onto a 6-well dish as 
described in section 2.2. Three wells were pre-treated with forskolin 
[lOpM] for 6hr before addition o f G-CSF [lOng/ml] and GM-CSF 
[lOng/ml] to the respective well for 30min (n=3). Cell lysates were 
prepared as described in section 2.4.1. and protein content equalised 
prior to SDS-PAGE fractionation. The proteins were then transferred 
onto nitro-cellulose before immunoblotting with total STAT3 and 
phospho-Tyr705-STAT3 antibodies. Two one-sample t-tests were 
performed on the data presented in this graph. The first was used to 
compare average densitometry measurement o f STAT3 in cells treated 
with G-CSF Vs. cells treated with G-CSF + Fsk. A p value o f 0.0019
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was obtained therefore pre-ti'eatment with Fsk did not statistically 
increase G-CSF induced levels of STATS. The second one sample t- 
test compared cells treated with GM-CSF Vs GM-CSF+Fsk a p-value 
of 0.0018 was obtained which shows that pre-treatment with Fsk did 
not statistically increase GM-CSF induced levels of STATS.
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Figure 3.15 Effect of Fsk pre-treatment on G-CSF/GM-CSF induced ERK-1 
phosphorylation. U937 cells were plated into a 6-well dish as 
described in section 2.2. Three wells were pre-treated with forskolin 
[lOpM] for 6hrs before addition o f G-CSF [lOng/ml] and GM-CSF 
[lOng/ml] to the respective well for 30min (n=3). Cell lysates were 
prepared as described in section 2.4.1. and the protein content 
equalised prior to SDS-PAGE fractionation. The proteins were then 
transferred onto nitro-cellulose before immunoblotting with the 
phospho-ERKl,2 and phospho-Thr202,Tyr204-ERKl,2 antibodies. 
The ERK-1 signal was stronger than that recorded for ERK-2 therefore, 
average densitometry was used to produce the graph presented above.
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Average densitometry readings of ERK-1 were compared using a one- 
sample t-test. For G-CSF Vs G-CSF + Fsk p=0.010 therefore Fsk 
significantly reduces ERK-1 in U937 cells (*). A one sample t-test was 
also employed to compare average ERK-1 in cells treated with GM- 
CSF Vs. GM-CSF + Fsk to produce a p-value of 0.259 therefore Fsk 
does not significantly reduce levels of ERK-1 in U937 cells.
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These results of these experiments prove that forskolin is capable of reducing levels 
of phoshpo-STAT3 and phospho-ERKl,2 in G-CSF stimulated cells and phospho- 
STAT3 in GM-CSF stimulated cells. This implies elevated levels of cAMP are able to 
reduce cytokine signalling in U937 cells. However, the mechanism by which cAMP is 
able to contribute to this response has yet to be ascertained.
3.6 Relationship between SOCS3 induction and cAMP
To this point, results have established that an increase in cAMP is linked to increased 
expression of SOCS3, and that elevated levels of cAMP are capable o f diminishing 
cytokine signaling via the G-CSFR and GM-CSFR. However, the mechanism by 
which cAMP is able to induce SOCS3 remains unknown.
As has been discussed in section 1.8.1, cAMP signals via various downstream 
effectors, including Epac and PKA. In order to establish involvement of Epac or PKA 
in the induction of SOCS3, U937 cells were treated for 6hrs with a variety of agents 
These included a PKA inhibitor (H89), a selective PKA activator (6Be-cAMP), and a 
selective Epac activator (8-pCPT-2-0-Me-cAMP) {Christensent et al, 2003). Levels 
of induced SOCS3 were monitored as a direct assessment of the effect of each agent. 
The results of these experiments are displayed in figure 3.16.
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Figure 3.16 Effects of cAMP signalling pathway activators on SOCS3 
induction in U937 cells. U937 cells split into a 6-well plate as 
described in section 2.2. Each well was treated with a combination of 
agents (0, Fsk[10pM], Fsk[10pM]+H89[5pM], 6Be-cAMP[50pM], 8- 
pCPT-2-O-Me-cAMP[0.1mM]), for 6hr (n=3). After this period, cell 
lysates were prepared according to section 2.4.1 and the protein 
content o f each was normalised prior to fractionation by SDS-PAGE. 
The proteins were transferred onto nitro-cellulose and probed using a 
tubulin and SOCS3 antibodies. The graph shows that SOCS3 
expression is significantly greater in Fsk and Fsk+H89 treated cells 
compared to cells treated with aôBe-cAMP and 8P-CPT,
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These results suggest SOCS3 is induced by a cAMP dependent, PKA/ERK 
independent pathway. This implies involvement o f a separate cAMP pathway. Based 
on these results it was decided to test the ability o f 6Be-cAMP and 8-pCPT-O-Me- 
cAMP to activate the ERK pathway, to ensure that both compounds were active. The 
results o f this experiment are displayed below in figure 3.17.
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Figure 3.17 Effects of H89, 6Be-cAMP and 8-pCPT-O-Me-cAMP on ERK 
activation in U937 cells. U937 cells split into a 6-well plate as 
described in section 2.2. Each well was treated with a combination of 
agents (0, Fsk[10pM], Fsk[10pM]+H89[5pM], 6Be-cAMP[50pM], 8- 
pCPT-2-O-Me-cAMP[0.1mM]), for 6hr (n=3). After this period, cell 
lysates were prepared according to section 2.4.1 and the protein 
content o f each was normalised prior to fractionation by SDS-PAGE. 
The proteins were transferred to nitrocellulose followed by 
immunoblotting with total ERK and phospho-Thr202,Tyr204-ERKl,2 
antibodies. Both 6Be-cAMP and 8-pCPT-O-Me-cAMP caused 
increased phosphorylation o f ERK thereby suggesting that both 
compounds were active.
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S0CS3 induction is controlled by various signalling pathways, all capable of 
activating transcription of the S0CS3 gene. Ultimately, cAMP appears to be involved 
at some stage in this process. For example, previous literature has stated that cAMP is 
capable of direct activation of p38 {Chio et al, 2004). Furthermore, results from this 
study show that elevated levels of cAMP are able to activate components of the 
Ras/Raf/ERK pathway.
To further investigate the involvement of defined signalling pathways in cAMP- 
mediated induction of S0CS3, stimulation experiments were carried out using a set of 
signalling pathway inhibitors. An ERK inhibitor (U0126), a selective inhibitor of p38 
(SB203580) and a JAK inhibitor were incubated with U937 cells for 6hr in the 
absence and presence of Fsk. The results of these experiments are recorded in figure 
3.17.
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Figure 3.17 Effects of signalling pathway inhibitors of Fsk-stimulated SOCS3 
induction in U037 cells. U937 cells were pre-treated with a each 
inhibitor (U 0126[lpM ], JAK inhibitor[0.5pM], SB203580[10mM]) 
for 30mins before addition o f Fsk[10pM] for 6hrs (n=3). Cell lysates 
were prepared as described in section 2.4.1 and the protein content of 
each lysate was normalised prior to fractionation by SDS-PAGE. The 
proteins were transferred onto nitro-cellulose and probed using a 
SOCS3 antibody. SOCS3 expression is significantly greater in the cells 
treated with Fsk. The graph illustrates there is no significant difference 
in SOCS3 expression between each inhibitor treatment.
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This experiment shows that none o f the inhibitors diminished SOCS3 induction in 
response to Fsk. This suggests an alternative signalling pathway is utilised by cAMP 
to induce SOCS3.
Since initial submission o f this thesis, my colleagues have performed efficacy tests on 
two o f the inhibitors used in the previous experiment. I have included the results o f  
here for prosperity.
U937 cells were treated with pre-treated with each inhibitor prior to stimulation o f the 
cells with known ERK and p38 agonists. The results o f each experiment are 
represented in figures 3.18 and 3.19.
Phospho-ERK1,2 
GAPDH
1/xM PMA, 5 min 
U0126, 30 min preinc
Figure 3.18 Effects of U0126 on ERK activation in U937 cells. U937 cells were 
pre-treated with U0126 for 30mins prior to a 5min incubation with 
PMA. Cell lysates were prepared as described in section 2.4.1 and the 
protein content o f each lysate was normalised prior to fractionation by 
SDS-PAGE. The proteins were transferred to nitrocellulose followed 
by immunoblotting with phospho-Thr202, Tyr204-ERK1,2 antibodies. 
GAPDH was used as a loading control. U0126 was clearly active since 
it was capable o f inhibiting the phospho-ERK signal observed in cells 
treated with PMA alone.
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Figure 3.19 Effects SB203580 on Phospho-p38 activation in U937 cells. U937 
cells were pre-treated with SB203580 for 30mins prior to a 5min 
incubation with Ansiomycin. Cell lysates were prepared as described 
in section 2.4.1 and the protein content o f each lysate was normalised 
prior to fractionation by SDS-PAGE. The proteins were transferred to 
nitrocellulose followed by immunoblotting with Rabbit anti- 
phosphoThr 180/Tyr 182-p3 8 antibodies. GAPDH was used as a loading 
control. U0126 was clearly active since it was capable o f inhibiting the 
phospho-ERK signal observed in cells treated with PMA alone.
No efficacy testing has been performed on the JAK inhibitor to date however, the 
concentration used is optimal as determined by abolition o f IL-6-mediated STAT3 
phosphorylation in vascular endothelial cells {Palmer, personal communication).
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CHAPTER 4
DISCUSSION
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4.1 Fsk/cAMP-mediated accumulation of SOCS3
Fsk induced SOCS3 in both U937 myeloid and FIL60 promyoblast cells. The optimal 
conditions for Fsk-induced S0CS3 expression was a 6hr incubation period at a 
concentration of lOpM. Fsk elevates intracellular cAMP levels by binding and 
activating adenylyl cyclase. Therefore it was concluded that elevated cAMP is 
responsible for induction of SOCS3 in both cell lines. Treatment with polymyxin B 
had no effect on the maximal level of S0CS3 expression induced by Fsk. Polymyxin 
B eliminates LPS generated S0CS3 thus, it was concluded that contamination of the 
Fsk preparation with LPS does not contribute to the SOCS3 induction obtained in this 
study.
Interestingly, the proteasome inhibitor (MG 13 2) had minimal effect on the 
accumulation of SOCS3 in both U937 and HL60 cells. SOCS3 turnover is a tightly 
regulated process (Hanada et al, 2003). The SOCS box region is responsible for 
regulating the stability of the protein, by mediating an intracellular interaction with an 
elongin C-containing complex (Haan, S et al 2003). Phosphorylation of S0CS3 at 
two tyrosine residues within the conserved SOCS box, Tyr204 and Tyr221, appears to 
inhibit the SOCS3-elongin C interaction and trigger proteasome-mediated S0CS3 
degradation (Haan, S et al 2003). Therefore, the minimal effect of MG-132 in U937 
cells in particular may suggest that increased cAMP has no effect on tyrosine 
phosphorylation of SOCS3. Tyrosine phosphorylation of SOCS3 is thought to be 
mediated predominantly by the Src family tyrosine kinases (Sommer U, et al 2005). 
However, there is no convincing evidence to link elevated cAMP with regulation of 
Src kinases, therefore the lack of effect of MG-132 is consistent with this hypothesis.
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SOCS3 stability can also be increased by a separate phosphoiylation event on the N- 
terminus o f the protein by Pirn-1 which encodes an oncogenic serine/threonine kinase 
(Peltola K J et al 2004). Pim-1 is a target gene of STAT5, which plays a critical role in 
cytokine-induced survival of heamatopoietic (Peltola KJ et al 2004). Pim-1 is a 
component of an inhibitory feedback pathway which serves to reduce STAT-5 
activity. During this process, Pim-1 interacts directly with SOCSl and S0CS3 to 
potentiate their inhibitory effects on STATS. This is thought to occur via a 
phosphorylation-mediated stabilisation of the SOCS proteins (Peltola KJ et al 2004). 
Currently, there is no evidence to support cAMP regulation of Pim-1. However, 
cAMP may be linked to increased activity of a kinase capable of phosphoiylating the 
same sites on S0CS3, thus stabilising the protein by preventing proteasomal 
degradation and providing resistance to MG-132.
To test if  elevated cAMP produces a stabilising phosphorylation of SOCS3 thus 
accounting for the minimal effect of MG-132 on S0CS3 accumulation, future 
experiments may involve ^^P-radiolabelling U937 cells prior to treatment with Fsk. 
By performing subsequent immunoprécipitation of S0CS3, it would then be possible 
to determine whether increased cAMP causes an increase in Ser/Thr phosphorylation 
ofSOCS3.
4.2 Effects of Fsk on cytokine signalling
Based on the results obtained in this study, it can be concluded that G-CSF and GM- 
CSF can induce phosphorylation of STATl, STAT3 and ERK in U937 cells. This is 
consistent with previous studies which demonstrated that G-CSF signals via the 
JAK/STAT and Ras/Raf/ERK pathways (Akbarzadeh et al, 2001). Results also
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showed that increased cAMP diminished G-CSF and GM-CSF-induced phosho- 
STAT3 andphospho-ERKl,2.
Elevated cAMP is coupled to an increase in S0CS3 expression and in turn, S0CS3 
has been shown to selectively bind the G-CSF receptor to block signalling in vivo 
(Hortner, et al, 2002). It is therefore feasible to suggest that the Fsk-induced increase 
in SOCS3 is responsible for the decrease in phospho-STAT3 and phospho-ERK 1,2. 
However, in order to definitively address a role for SOCS-3, one would need to 
determine the consequences of blocking SOCS-3 induction by Fsk on Fsk-mediated 
inhibition of G-CSF signalling. To block SOCS-3 accumulation and unequivocally 
assign a role for it in mediating cAMP’s effect, one could use either siRNA or 
antisense RNA strategies. In this report, it is also important to remember that we 
cannot, at the moment, exclude other possible mechanisms for this response. For 
example, SHP-1, a tyrosine phosphatase induced by G-CSF in certain cells, is able to 
dephosphorylate both JAKs and cytokine receptors (Haque et al 1998), thus 
theoretically preventing subsequent phosphoiylation of ERK proteins. It is also 
theoretically possible that the receptor could be down-regulated in response to 
increased levels of cAMP, thereby reducing the response to Fsk which is represented 
by diminished levels of phospho-ERK 1,2 as observed here.
In order to ascertain the mechanism underlying the reduction in G-CSF receptor 
signalling following a cAMP-induced SOCS3 upregulation, it would be necessary to 
examine the existence/importance of the alternative mechanisms suggested above.
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This could be achieved by examining the following issues:
1. Do tyrosine phosphatase inhibitors block the inhibitory effect of Fsk on inhibiting 
GCSF induced phosphorylation of STATS and ERK1,2? If this is not found to be 
true, presumably SHP-1 is not involved in mediating the effects of cAMP.
2. Does the inhibition of protein synthesis block the inhibiting effects of cAMP? If 
this is observed, in conjunction with a lack of effect of Tyr phosphatase inhibitors, 
it could suggest that cAMP-mediated induction of SOCS3 may be responsible for 
the cAMP-mediated decrease in levels of phospho-STAT3 and phospho-ERK 1,2.
4.3 Analysis of the signalling pathway mediating Fsk induction of SOCS3
Fsk is capable of inducing SOCS3 and it has been suggested that Epac and PKA may 
be involved in this process (de Rooj et ai, 1998. Kopperund et al, 2003). This study 
investigated the potential role of Epac and PKA in Fsk-induced S0CS3 using 
selective activators and inhibitors. PKA and Epac activators (6Be-cAMP, 8-pCPT-2- 
O-Me-cAMP respectively) did not induce SOCS3 in U937 cells. Furthermore, a PKA 
inhibitor (H89) did not inhibit Fsk-induced S0CS3. Thus, it was concluded that PKA 
and Epac are not involved in the Fsk mediated induction of S0CS3.
In further consideration of the PKA response (or lack there of), even though H89 did 
not inhibit Fsk stimulated SOCS3 in U937 cells, the concentration used is effective in 
inhibiting PKA function in human umbilical vein endothelial cells (HUVECs) at the 
concentration used here {Sands et al., submitted for publication), as judged by 
abolition of Fsk-stimulated Seri33 phosphorylation of cyclic AMP response element 
binding protein (CREB). It was not possible to reproduce this experiment using U937
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cells as veiy high basal levels of phospho-CREB were recorded, probably due to the 
action of other CREB kinases (data not shown). However, the lack of reduction of 
Fsk-induced SOCS3 expression in response to the PKA-inhibitor (H89), coupled with 
the lack of effect of the selective PKA activator (6Be-cAMP) would suggest the 
involvement of a PKA-independent pathway. One possible mediator of the PKA- 
independent effects of cAMP is Epac. A selective Epac activator (8-pCPT-2-0-Me- 
cAMP) has been shown to induce S0CS3 in HUVECs {Sands et al, submitted for  
publication). However, this effect could not be reproduced in U937 cells using 
batches of 8pCPT-2-0-Me-cAMP that were active in HUVECs. Due to this lack of 
response, Epac is likely not responsible for cAMP-mediated induction of SOCS3 in 
U937 cells. In addition, while unable to induce SOCS-3, 6Be~cAMP and 8-pCPT-2- 
0-Me-cAMP were each able to stimulate the phosphoiylation of ERK in U937 cells, 
confirming that both dings were active under these conditions. In view of these 
results, the role of cAMP in S0CS3 induction is independent of PKA and Epac and as 
such, it is possible that an unknown and as yet uncharacterised sensor of cAMP is 
responsible.
To identify any new intracellular sensor of cAMP in these cells, cAMP-conjugated 
argarose could be used as an affinity pui’ification probe for isolating cAMP-binding 
proteins. After releasing PKA and Epac by elution with 6Be-cAMP and 8-pCPT-2-0- 
Me-cAMP respectively, any remaining cAMP-binding proteins could be eluted and 
identified by mass spectometiy and peptide mass fingerprinting.
Final experiments attempted to address the signalling pathway mediating SOCS3 
induction via cAMP. A set of inhibitors were selected based on their ability to block
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specific pathways that could be involved in cAMP induction of SOCS3. The MEK 
inhibitor (U0126) blocks Fsk-induced SOCS-3 in HUVECs {Sands et al, submitted 
for publication), SB203580 is a selective inhibitor of p38 sti'ess activated kinase 
which is activated by cAMP in some cell types and a JAK inhibitor which would 
block the JAK/STAT pathway directly thereby preventing STAT-mediated SOCS3 
transcription. Experiments in HUVECs and fibroblasts demonstrated that each 
inhibitor was active at the concentrations used. Results showed that none of the 
inhibitors were capable of attenuating Fsk induced SOCS3. This adds further support 
to the involvement of an independent and as yet undefined mechanism for cAMP 
related-S0CS3 induction.
As more questions evolve from the results of this study, it is important to consider the 
primary mechanisms by which cytokines induce SOCS3 transcription.
Cytokines induce S0CS3 via activation of the JAK-STAT pathway which leads to 
STAT-mediated transcription of the SOCS3 gene {Hanada et al, 2003). However, 
elevated cAMP does not appear to utilise this mechanism since the JAK inhibitor does 
not block S0CS3 induction. The combination of JAK inhibitor used here is effective 
when applied to HUVECs where an abolition of sIL-6Ra/IL-6-induced SOCS3 is 
observed {Sands et al, submitted for publication). This effect is consistent with very 
little evidence in the literature to suggest that increased cAMP can activate the JAK- 
STAT pathway.
Attenuation of ERK with MEK inhibitor (U0126) also has no effect on induction of 
S0CS3. This is consistent with the fact that Fsk, 6Be-cAMP and 8-pCPT-2-0-Me- 
cAMP can all increase levels of phosphorylated ERK in U937 cells, but only Fsk can
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induce SOCS3. HUVECs exhibit a contrasting response, where U0126 abolishes 
c AMP-mediated SOCS3 induction (Sands et al, submitted for publication) Therefore, 
while the ability of elevated cAMP to induce S0CS3 appears to be conserved across 
different cell lines, the molecular mechanisms involved in this process may be 
distinct.
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